

### REMARKS

Claims 1-42 and 49-55 were canceled or withdrawn previously;  
Claims 43-48 and 56-65 were pending; and  
Claims 43-48 and 56-65 were allowed.

This is in response to the *Ex parte Quayle* Action mailed August 28, 2003, with the two-month shortened response period set to expire Tuesday, October 28, 2003.

At the beginning, Applicants want to thank the Examiner for allowing Claims 43-48 and 56-65 in the *Ex parte Quayle* Action.

Here, Applicants seek the Examiner's permission to enter the amendments submitted herein. The amendments are made in compliance with the requirements set forth in the *Ex parte Quayle* Action and are directed to formal matters only. Consequently, Applicants believe the amendments would place the present application in condition for allowance and, thus, should be entered.

As indicated by the Examiner in the *Ex parte Quayle* Action, the nucleotide sequence disclosed on page 20, line 27, and the amino acid sequence appeared in the last line of Table 14 on page 78 of the specification do not have sequence identification numbers (i.e. SEQ ID NOs). In compliance with 37 C.F.R. §§ 1.821 through 1.825, Applicants hereby amend the specification by assigning appropriate SEQ ID NOs to the sequences. Applicants note, however, that the amino acid sequence in the last line of Table 14 on page 78 of the specification has been previously assigned SEQ ID NO: 29, which is included in the Sequence Listing submitted previously. However, due to a typographic error, SEQ ID NO: 29 is not included in Table 14 on page 78. This error is corrected by amending the last line of Table 14 to recite SEQ ID NO: 29.

The nucleotide sequence disclosed on page 20, line 27, has likewise not been designated a sequence identification number. Nor is this sequence included in the Sequence Listing submitted previously. To correct this error, a new sequence identification number, i.e. SEQ ID NO: 33, is designated to the nucleotide sequence disclosed on page 20, line 27. Consequently, a new Sequence Listing and a newly executed statement under 37 C.F.R. § 1.825 are submitted herein to replace the ones submitted previously.

In a separate envelope, a computer readable form (CFR) of the Sequence Listing, together with a paper copy of the Sequence Listing and a copy of the statement, are sent to "Mail Stop Sequence" at the same time this Response is mailed

No new matter is added. Entry of the Sequence Listing submitted herein is respectfully requested.

In anticipation that the instant amendment would place the application in condition for allowance, a Notice of Allowance is courteously solicited.

### **CORRESPONDENCE AND FEES**

No fee is necessitated by the foregoing amendment. However, should this be in error, authorization is given herein to charge Deposit Account No. 03-3839.


Please address all correspondence to Intellectual Property Docket Administrator, Gibbons, Del Deo, Dolan, Griffinger & Vecchione, One Riverfront Plaza, Newark, NJ 07102-5497. Telephone calls should be directed to Michael Dai at (973) 596-4489 and fax communications should be sent to him directly at (973)-639-8311.

09/775,743

Should there be any questions, or any matters that may be resolved by telephone call, the Examiner is invited to contact the applicants' attorney at the number above.

Respectfully submitted,

Date: September 12 2003

A handwritten signature in black ink, appearing to read 'M. Michael Dai', is written over a horizontal line.

M. Michael Dai, Reg. No. 47,512  
Attorney for Applicants  
Gibbons, Del Deo, Dolan,  
Griffinger & Vecchione  
One Riverfront Plaza  
Newark, New Jersey 07102-5497